Research and Development

Astellas Pharma Europe, the European subsidiary of Tokyo-based Astellas Pharma, has appointed Mike Crooks as its new UK general manager. …

Bayer and Onyx’s colorectal cancer drug regorafenib increased overall survival for late-stage patients, according to new data. The Phase III …

Savient Pharmaceuticals has appointed David Veitch as the new president of its European division. Veitch joins the specialist biopharma firm …

Pfizer and Medivation have written off their Alzheimer’s candidate dimebon after another Phase III failure.  The firms said a 12-month …

Novartis has said it will not close down a plant in Switzerland that had been due for closure, and has …

Roche is still withholding Tamiflu data from researchers, claims the British Medical Journal. Two years after Roche said it would …

NICE, or the National Institute for Health and Clinical Excellence, to give it its full title, is world famous for …

Princeton, NJ January 17, 2012 – Signaling a further commitment to expand its business model in the Pacific Rim and …

Oxford BioTherapeutics has appointed C. Glenn Begley as a senior clinical advisor and non-executive director of the firm.  Dr Begley, …

A round-up of developments in the contract research sector, including updates on Charles River Labs, ShangPharma, Icon, Covance, AAIPharma and …

Otsuka and UCB have scaled back the scope of their collaboration, and will now focus on developing drugs for the …

AstraZeneca has used a recent healthcare conference in San Francisco to call for new drug development partners. Speaking at the …

Novartis will slash 1,960 jobs in the US as it prepares for life without its blockbuster medicine Diovan. The hypertension …

A new survey shows pharma is not prepared to deal with the tough year ahead as many blockbuster drugs begin …

A former Merck research site in Scotland has been given a new lease of life as a biotech science park. …